JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new drugs; Roche launches smart, point-of-care glucose monitor
JPM22, Day 3: BeiGene, Ionis promise ‘tidal wave’ of new [...]
JPM22, Day 3: Intellia, Editas plan to double down on gene editing data in 2022; Roche launches smart glucose monitor
JPM22, Day 3: Intellia, Editas plan to double down on [...]
Sanofi makes $75M preclinical bet to join Roche, Novartis and more in congested Parkinson’s field
Sanofi makes $75M preclinical bet to join Roche, Novartis and [...]
Daiichi axes 60-person Plexxikon R&D facility in California to free up cash for ADC development
Daiichi axes 60-person Plexxikon R&D facility in California to free [...]
Regeneron, 2seventy name the target of their first solid tumor CAR-T, aim for 2023 IND
Regeneron, 2seventy name the target of their first solid tumor [...]
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices [...]
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go [...]
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for $45M cancer research deal
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for [...]
BioMarin’s hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
BioMarin’s hemophilia A gene therapy hits goal in phase 3, [...]
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Maze Therapeutics navigates $190M financing round as it plots course [...]